240 related articles for article (PubMed ID: 31349062)
21. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026
[TBL] [Abstract][Full Text] [Related]
22. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.
Li D; Wang D; Johann DJ; Hong H; Xu J
Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Bubendorf L; Zoche M; Dafni U; Rüschoff JH; Prince SS; Marti N; Stavrou A; Kammler R; Finn SP; Moch H; Peters S; Stahel RA
Lung Cancer; 2022 Dec; 174():27-35. PubMed ID: 36283211
[TBL] [Abstract][Full Text] [Related]
24. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
Li W; Qiu T; Ling Y; Gao S; Ying J
Mol Oncol; 2018 May; 12(5):677-689. PubMed ID: 29518290
[TBL] [Abstract][Full Text] [Related]
25. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
26. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
[TBL] [Abstract][Full Text] [Related]
27. Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas.
Wang C; Liang H; Lin C; Li F; Xie G; Qiao S; Shi X; Deng J; Zhao X; Wu K; Zhang X
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480292
[TBL] [Abstract][Full Text] [Related]
28. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.
Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N
J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449
[TBL] [Abstract][Full Text] [Related]
29. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
[TBL] [Abstract][Full Text] [Related]
30. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
[TBL] [Abstract][Full Text] [Related]
31. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
[TBL] [Abstract][Full Text] [Related]
32. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
33. The emerging development of tumor mutational burden in patients with NSCLC.
Zhang Y; Wang L; Li R; Liu B
Future Oncol; 2020 Mar; 16(9):469-481. PubMed ID: 32048882
[TBL] [Abstract][Full Text] [Related]
34. Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.
Sung MT; Wang YH; Li CF
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563486
[TBL] [Abstract][Full Text] [Related]
35. Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma.
Ma K; Huang F; Wang Y; Kang Y; Wang Q; Tang J; Sun P; Lou J; Qiao R; Si J; Cao J; Miao L
Cancer Med; 2022 Nov; 11(22):4389-4397. PubMed ID: 35521981
[TBL] [Abstract][Full Text] [Related]
36. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
Vega DM; Yee LM; McShane LM; Williams PM; Chen L; Vilimas T; Fabrizio D; Funari V; Newberg J; Bruce LK; Chen SJ; Baden J; Carl Barrett J; Beer P; Butler M; Cheng JH; Conroy J; Cyanam D; Eyring K; Garcia E; Green G; Gregersen VR; Hellmann MD; Keefer LA; Lasiter L; Lazar AJ; Li MC; MacConaill LE; Meier K; Mellert H; Pabla S; Pallavajjalla A; Pestano G; Salgado R; Samara R; Sokol ES; Stafford P; Budczies J; Stenzinger A; Tom W; Valkenburg KC; Wang XZ; Weigman V; Xie M; Xie Q; Zehir A; Zhao C; Zhao Y; Stewart MD; Allen J;
Ann Oncol; 2021 Dec; 32(12):1626-1636. PubMed ID: 34606929
[TBL] [Abstract][Full Text] [Related]
37. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.
Zhou J; Sanchez-Vega F; Caso R; Tan KS; Brandt WS; Jones GD; Yan S; Adusumilli PS; Bott M; Huang J; Isbell JM; Sihag S; Molena D; Rusch VW; Chatila WK; Rekhtman N; Yang F; Ladanyi M; Solit DB; Berger MF; Schultz N; Jones DR
Clin Cancer Res; 2019 Dec; 25(24):7475-7484. PubMed ID: 31455678
[TBL] [Abstract][Full Text] [Related]
39. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
[TBL] [Abstract][Full Text] [Related]
40. Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
Pinato DJ; Urus H; Newsom-Davis T; Du Parcq P; Belessiotis K; Mapara L; Gupta N; Power D; Weir J; Wong CN; Ratnakumaran RP; Dominy K; Khorashad J; Bower M
J Immunother; 2020; 43(2):53-56. PubMed ID: 31567705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
